Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Dyadic International, Inc.
JUPITER, Fla., May 6, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today that they have strengthened their European leadership team with the addition of two senior level positions.
Dr. Ronen Tchelet has joined the Company's European leadership team as the Vice President of Business Development. He joins Dyadic from Codexis, where he served as Vice President and Managing Director of their Research and Development laboratories in Hungary. Prior to Codexis, Dr. Tchelet served as Chief Technology Officer of Biotechnology for the API division of Teva Pharmaceuticals. In this new position, Ronen will play a key role in driving business development efforts across all markets, as well as, Dyadic's internal and third party research and development projects.
"Having worked with Dyadic's C1 expression system for over six years while at Codexis, a Dyadic licensee, I became intimately familiar with the versatility and commercial potential of the C1 technology platform. Dyadic's C1 technology has the ability to produce large volumes of high-performance enzymes and other proteins at low cost. I look forward to helping leverage the C1 technology in Dyadic's existing markets, as well as, the vast potential in untapped markets," said Dr. Tchelet.
We are also excited to announce that next month Andre Klaassen will be joining Dyadic's European sales team as the new Director of Sales for Europe. Andre has spent the past two decades in enzyme sales at DuPont and Genencor in a variety of senior roles. He began his career in engineering and operational roles at Gist-Brocades, now part of DSM. As Director of Sales, Andre will manage the day-to-day European sales operations and help support new product development in our Dutch research facility. In addition, Andre will provide key account management, and assume global responsibility for our starch and alcohol enzyme business.
"I am excited by the potential to help grow sales of Dyadic's current enzyme products within Europe, Dyadic's fastest growing market. But what really convinced me to join Dyadic was the cutting edge research and development capabilities at Dyadic Netherlands that may be leveraged to discover, develop, manufacture and commercialize new enzymes across virtually every industry. Using three decades of market experience, I hope to make a major contribution to Dyadic's new product development," said Klaassen.
"Both Ronen and Andre have extensive experience within the biotechnology industry. Their enthusiasm, energy and creativity are an excellent fit for our entrepreneurial culture and we expect them to play an important role in growing our business within Europe and globally. The addition of these two roles further illustrates our commitment to augmenting our leadership team worldwide, and we expect to make additional announcements in the coming months," added Danai Brooks, Dyadic's Chief Operating Officer.
Both Dr. Tchelet and Mr. Klaassen will be based out of our research center in Wageningen, Netherlands.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com. Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/quote.
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic's ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; (4) Dyadic's research and development efforts, (5) the outcome of the current litigation by Dyadic against its former counsel and (6) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Annual Report filed with the OTC Markets Group on March 31, 2014.
©2012 PR Newswire. All Rights Reserved.